Vivus Inc (NASDAQ:VVUS) Has Decline in Shorts

June 14, 2018 - By Hazel Jackson

Investors sentiment increased to 1 in 2018 Q1. Its up 0.43, from 0.57 in 2017Q4. It improved, as 7 investors sold VIVUS, Inc. shares while 12 reduced holdings. 8 funds opened positions while 11 raised stakes. 22.03 million shares or 14.97% less from 25.91 million shares in 2017Q4 were reported.
Menta Capital Ltd Com holds 0.01% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS) for 156,421 shares. Tortoise Invest Mgmt Lc invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Moreover, Bancorp Of Montreal Can has 0% invested in VIVUS, Inc. (NASDAQ:VVUS). Pnc Financial Gp Inc accumulated 12,650 shares or 0% of the stock. Moreover, United Svcs Automobile Association has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 17,507 shares. Hanson Mcclain Inc has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 250 shares. Morgan Stanley stated it has 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Jpmorgan Chase accumulated 2,500 shares or 0% of the stock. Guggenheim Ltd Liability invested in 0% or 27,963 shares. California Pub Employees Retirement System invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Benjamin F Edwards And Communication holds 0% or 200 shares. Northern Tru accumulated 279,536 shares. Moreover, Creative Planning has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 170,735 shares. Acadian Asset Management Ltd Liability Corp reported 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Goldman Sachs Group Inc holds 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS) for 32,226 shares.

The stock of Vivus Inc (NASDAQ:VVUS) registered a decrease of 6.42% in short interest. VVUS’s total short interest was 4.90 million shares in June as published by FINRA. Its down 6.42% from 5.24M shares, reported previously. With 251,800 shares average volume, it will take short sellers 20 days to cover their VVUS’s short positions. The short interest to Vivus Inc’s float is 5.39%.

The stock decreased 0.56% or $0.0046 during the last trading session, reaching $0.8225. About 603,111 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 18.39% since June 14, 2017 and is downtrending. It has underperformed by 30.96% the S&P500.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $87.23 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It currently has negative earnings. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

More news for VIVUS, Inc. (NASDAQ:VVUS) were recently published by: Streetinsider.com, which released: “VIVUS (VVUS) Closes Acquisition of PANCREAZE and Previously Announced Financing Transaction” on June 11, 2018. Benzinga.com‘s article titled: “Benzinga Pro’s 5 Stocks To Watch Today” and published on June 11, 2018 is yet another important article.

VIVUS, Inc. (NASDAQ:VVUS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: